“Biogen has been, and continues to be, committed to working with all stakeholders to ensure SPINRAZA is available as an option for people with SMA to treat this devastating disease,” said David Henderson, the managing director of Biogen Australia and New Zealand.
Expanded funding of SPINRAZA for treatment of pre-symptomatic SMA babies
March 4, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
New report highlights the potential health-system benefits of pharmacist prescribing
June 9, 2026 - - Latest News -
It was an unintentionally revealing discussion about the history and reality of agreements
June 9, 2026 - - Latest News -
R&D tax shake up risks sending Australia’s biotech talent and jobs overseas
June 9, 2026 - - Latest News -
Rare Cancers Australia co-founder Kate Vines recognised in King's Birthday Honours
June 8, 2026 - - Latest News -
Omico is evolving tumour genomics into hard evidence for precision oncology
June 8, 2026 - - Latest News -
The 'Dispatched' Podcast - Special episode
June 5, 2026 - - Podcast -
Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News

